Every material Form 8-K TEVA PHARMACEUTICAL INDUSTRIES LTD has filed with the SEC since September 16, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Teva reported third-quarter 2026 revenue of $4.4 billion, down 2% from a year earlier, as lower U.S. sales of generic lenalidomide capsules offset growth in its key innovative brands. GAAP diluted EPS fell to $0.20 from $0.37, while non-GAAP diluted EPS rose to $0.86 from $0.78, and Teva raised 2026 revenue outlooks for AUSTEDO, AJOVY and UZEDY.
Q3 2026 revenues were $4.4 billion, down 2% in both U.S. dollars and local currency, mainly due to lower lenalidomide capsule revenues in the U.S.
GAAP diluted EPS was $0.20 versus $0.37 in Q3 2025; non-GAAP diluted EPS was $0.86 versus $0.78.
Operating income was $714 million versus $882 million a year earlier, mainly due to higher tangible asset impairments and higher legal settlements and loss contingencies.
2026 revenue outlooks raised for AUSTEDO to $2.55–$2.65 billion, AJOVY to $930–$960 million and UZEDY to $290–$310 million; total 2026 revenue outlook is $16.7–$17.0 billion.
Teva's board elected Dr. David J. Brailer as a director, effective November 3, 2026, serving until the 2027 annual meeting. The board determined he is independent under NYSE rules and expects him to join the Human Resources and Compensation and Compliance Committees. The filing says he will receive the same non-executive director compensation described in the March 31, 2026 proxy statement.
Board elected Dr. David J. Brailer on October 27, 2026, effective November 3, 2026
Term runs until Teva's 2027 annual meeting of shareholders
Board determined he is independent under NYSE listing rules; expected to serve on Human Resources and Compensation and Compliance Committees
Formerly Chief Health Officer of The Cigna Group (2022 to 2026) and former director of Walgreens Boots Alliance (2012 to 2021)
On September 16, 2026, Teva's subsidiaries issued €1.5 billion and $3.2 billion of senior unsecured notes due 2032 to 2037, guaranteed by Teva Pharmaceutical Industries. Teva plans to use the proceeds to fund conditional redemptions of several existing notes, pay related fees, and for general corporate purposes. The filing shows a refinancing of existing debt rather than a stated change in operations or results.
Euro notes: €1.0 billion of 4.250% notes due March 16, 2033, and €500 million of 4.625% notes due September 16, 2036
USD notes: $1.2 billion of 5.250% notes due January 16, 2032; $1.0 billion of 5.500% notes due January 16, 2034; and $1.0 billion of 5.750% notes due January 16, 2037
Conditional redemptions include up to $450 million of 4.750% notes due 2027 and up to €1.15 billion of 4.375% notes due 2030, reduced from up to €1.25 billion
Teva may redeem notes, or issue further redemption notices, at its sole discretion and is under no obligation to do so
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every TEVA PHARMACEUTICAL INDUSTRIES LTD filing is on SEC EDGAR ↗. 8-K briefs of other companies →